The 10-second takeaway
For the quarter ended March 31 (Q1), Sagent Pharmaceuticals beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share increased. GAAP earnings per share grew.
Margins grew across the board.
Sagent Pharmaceuticals logged revenue of $60.2 million. The seven analysts polled by S&P Capital IQ expected to see net sales of $55.3 million on the same basis. GAAP reported sales were 57% higher than the prior-year quarter's $38.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.17. The eight earnings estimates compiled by S&P Capital IQ anticipated -$0.03 per share. Non-GAAP EPS were $0.17 for Q1 versus -$0.30 per share for the prior-year quarter. GAAP EPS were $0.34 for Q1 against -$0.30 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 30.7%, much better than the prior-year quarter. Operating margin was 17.2%, much better than the prior-year quarter. Net margin was 16.3%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $57.6 million. On the bottom line, the average EPS estimate is $0.00.
Next year's average estimate for revenue is $238.1 million. The average EPS estimate is $0.09.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sagent Pharmaceuticals is outperform, with an average price target of $19.13.
- Add Sagent Pharmaceuticals to My Watchlist.